Kim Smith-Whitley - 01 Sep 2022 Form 4 Insider Report for Global Blood Therapeutics, Inc.

Role
Officer Title: EVP, Head of Research & Development
Signature
/s/ Miguel Carrillo, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
01 Sep 2022
Net transactions value
-$41,367
Form type
4
Filing time
06 Sep 2022, 19:00:34 UTC
Previous filing
03 Jun 2022
Next filing
06 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GBT Common Stock Options Exercise +2,208 +50% 6,588 01 Sep 2022 Direct F1
transaction GBT Common Stock Tax liability $41,367 -607 -9.2% $68.15 5,981 01 Sep 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBT Restricted Stock Units Options Exercise $0 -2,208 -12% $0.000000 15,460 01 Sep 2022 Common Stock 2,208 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
F2 Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 2,208 shares of Common Stock underlying the Reporting Person's RSUs.
F3 The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Remarks:

Officer Title: EVP, Head of Research & Development